C ardiovascular diseases (CVD) are the primary cause of death in women. 1 In the past decade, it has become clear that there is a strong relation of common complications of pregnancy, such as hypertensive disorders of pregnancy (HDP) and gestational diabetes mellitus (GDM), with future CVD events in women. [2] [3] [4] [5] [6] The findings have been acknowledged by the American Heart Association 2011 in its Guidelines on the Prevention of Cardiovascular Disease in Women, which stipulate that healthcare professionals should obtain pregnancy history as part of routine clinical intake and evaluate cardiovascular risk factors.
C ardiovascular diseases (CVD) are the primary cause of death in women. 1 In the past decade, it has become clear that there is a strong relation of common complications of pregnancy, such as hypertensive disorders of pregnancy (HDP) and gestational diabetes mellitus (GDM), with future CVD events in women. [2] [3] [4] [5] [6] The findings have been acknowledged by the American Heart Association 2011 in its Guidelines on the Prevention of Cardiovascular Disease in Women, which stipulate that healthcare professionals should obtain pregnancy history as part of routine clinical intake and evaluate cardiovascular risk factors. 1 Moreover, in the guidelines for the prevention of stroke in women, the American Heart Association recommends that women with preeclampsia should be evaluated 6 months to 1 year postpartum to assess and treat potential cardiovascular risk factors, including hypertension, obesity, smoking, and dyslipidemia. 7 A considerable proportion of women develop a complication of pregnancy. GDM affects as much as 5% to 9% of pregnancies, 8 whereas ≈10% of pregnancies are complicated by high blood pressure. 9, 10 The latter can be subdivided into preeclampsia and pregnancy-induced hypertension. Although these conditions generally subside after delivery, many of these women are predisposed to develop future type 2 diabetes mellitus (T2D), hypertension, and CVD. [11] [12] [13] [14] [15] [16] [17] As most studies focused on the risk of developing these cardiovascular risk factors, little is known about the time frame (years after the pregnancy) in which a woman with a history of HDP or GDM develops T2D and hypertension. [11] [12] [13] [14] [15] [16] [17] This information is of importance for the timing of effective screening programs to reduce the risk of CVD in women with these complications of pregnancy. Furthermore, it is unknown whether complications of pregnancy are independently associated with the risk of developing CVD because only a few studies have included hypertension and T2D as an intermediate. 16, 18 Hence, the aim of this study was to assess the impact of a self-reported history of HDP or GDM on the prevalence and age of onset of hypertension and T2D. In addition, the risk of T2D and CVD later in life was studied independent of the intermediates hypertension and T2D in a prospective cohort study.
Methods

Studied Population
The European Prospective Investigation into Cancer and Nutrition (EPIC)-NL cohort is the Dutch contribution to the EPIC and consists of the Monitoring Project on Risk Factors for Chronic Diseases (MORGEN) cohort and the Prospect cohort. 19 The MORGEN cohort consists of 22 654 men and women aged 20 to 66 years selected from random samples of the Dutch population in 3 cities in the Netherlands (Amsterdam, Doetinchem, and Maastricht). From 1993 to 1997, men and women were invited to participate in this study. The PROSPECT cohort includes 17 357 women aged 49 to 70 years who lived in the city of Utrecht and its surroundings and participated in the Dutch national breast cancer screening program between 1993 and 1997. At study enrollment, a general questionnaire was filled in by all participants and a physical examination was performed with blood samples. All participants gave their written informed consent, and the study complies with the Declaration of Helsinki and was approved by the Institutional Board of the University Medical Center Utrecht (PROSPECT) and the Medical Ethical Committee of TNO Nutrition and Food Research (MORGEN). The design, sampling strategies, and examination techniques of the cohort have been described in more detail previously. 20 In total, 29 751 women participated in the EPIC-NL study. For the present study, we excluded women who had never been pregnant (n=5877), without vital pregnancies (n=707), with missing data on pregnancy history (n=17), with no information on cardiovascular events (n=885), and with known T2D, hypertension, or CVD before the age of the first pregnancy (n=173). In total, 22 265 women remained for the analyses.
Obstetric History Information
With the questionnaire at study enrollment, information was collected on the number of pregnancies and live-born children. In addition, the duration of the first pregnancy was asked and its outcome. Also, women were asked, "Did you suffer from high blood pressure during pregnancy?" If affirmative, we regarded women to have had a HDP as done previously. 21 A similar question for GDM was asked. If a woman responded positively to this question, she was categorized in the GDM group.
Ascertainment of Cardiovascular Risk Factor at Study Enrollment
The questionnaire at study enrollment contained questions on demographic characteristics, presence of chronic diseases, and risk factors for chronic diseases, such as hypertension, smoking habits, and alcohol consumption. Smokers were categorized as current, past, or never smokers. Alcohol consumption was defined as current drinker, drinking <1 drink per week, past drinker, or never drinker.
At physical examination, body weight was measured in light indoor clothing without shoes to the nearest 0.5 kg with a floor scale (Seca, Atlanta, GA). Height was measured to the nearest of 0.5 cm with subjects wearing no shoes. Body mass index (BMI) was calculated as weight divided by height squared (kg/m 2 ). Obesity was defined as a BMI ≥30 kg/m 2 . In PROSPECT, systolic and diastolic blood pressure were measured twice at the right arm with an automated and calibrated oscillometric sphygmomanometer (Bosch & Son, Jungingen, Germany) with the subject in supine position. In MORGEN, systolic and diastolic blood pressure were measured in duplicate using a random zero sphygmomanometer in supine position on the left arm. The mean of the 2 measurements was calculated. In the present analyses, the diagnosis of hypertension at study enrollment was based on measured blood pressure levels (>140 mm Hg systolic or >90 mm Hg diastolic) or use of blood pressure lowering drugs. Only in the PROSPECT cohort (n=14 595), the age of onset was asked for those with self-reported hypertension.
Serum total and high-density lipoprotein cholesterol were measured in nonfasting blood samples using enzymatic methods. 20 Hypercholesterolemia was defined present when women reported that hypercholesterolemia had been diagnosed by a physician or when total cholesterol levels were 6.5 mmol/L or above.
Ascertainment of CVD Events and T2D
After the study enrollment examinations, participants were followed for the occurrence of T2D and CVD by linkage to several disease registries. CVD outcomes of interest for this study were ischemic heart disease (IHD), stroke, and a composite of cardiovascular events (CVD; Table S1 in the online-only Data Supplement). These outcomes were based on both fatal and nonfatal events. Whenever multiple events occurred, the first diagnosis was taken as end point. Follow-up was complete until January 1, 2006, for T2D. For the CVD outcome, women were followed to the first nonfatal cardiovascular event, death, and emigration or were censored at January 1, 2008.
Data on cardiovascular morbidity were obtained from the National Medical Registry using the Dutch Hospital Discharge register. Admission files have been filed continually from most general and university hospitals in The Netherlands since 1990. Data on sex, date of birth, dates of admission, and discharge were recorded whenever a patient was discharged from a hospital. Morbidity diagnoses were coded according to the International Classification of Diseases, Clinical Modification, Ninth Revision (Table S1 ). This database was linked to the cohort on the basis of birth date, sex, postal code, and general practitioner with a validated probabilistic method. 22 Information on vital status was obtained through linkage with the municipal administration registries. Prevalent cases of CVD were identified through linkage with the National Medical Registry (1990 Registry ( -1997 and by self-report using the baseline general questionnaire for cases before 1990.
Causes of death were obtained from Statistics Netherlands coded according to the International Classification of Diseases, Clinical Modification, Ninth Revision until 1996 and, after that, according to the International Classification of Diseases, Clinical Modification, Tenth Revision.
At study enrollment, information on T2D was obtained via self-report in the baseline questionnaire and linkage to the National Medical Registry (1990-1997) as described. Incident cases of T2D were identified via 2 follow-up questionnaires at 3 to 5 year intervals. Patients were asked whether diabetes mellitus was diagnosed, in what year, by whom, and what treatment they received. Diagnosis of T2D was also obtained from the National Medical Registry or detected by the use of a urinary glucose strip test, sent out with the first follow-up questionnaire, for detection of glucosuria (only in PROSPECT). 23 The diagnosis of T2D was coded according to the International Classifications of Diseases, Clinical Modification, Nineth revision. Both prevalent and incident T2D cases identified by any of these methods were verified against information from the participants' general practitioner or pharmacist through mailed questionnaires. T2D was considered to be present when the general practitioner or pharmacist confirmed the diagnosis. 24 Only cases confirmed by either the general practitioner or pharmacist were included in the analyses.
Statistical Analysis
Because incomplete case analyses lead to loss of statistical power, 25, 26 Table S2 . To examine the influence of imputation of missing values of the pregnancy complications HDP and GDM on the risk of developing CVD and T2D, Cox proportional hazards models described hereafter were performed with and without imputation of these pregnancy complications (Tables S3 and S4 ). Because no differences in results have been found, missing values of HDP (n=533) and GDM (n=3366) were imputed as well. Population characteristics were described by complication of pregnancy using mean and SD for continuous variables and number and frequency for categorical variables. Differences in age of onset of hypertension and T2D between women with and without a positive history for HDP and GDM were calculated using ANCOVA analyses, including the covariates HDP or GDM when appropriate; age at delivery; and BMI. Information on age of onset was available for hypertension (self-reported) in PROSPECT only until study enrollment examination and for T2D (self-report verified) until the end of follow-up in 2006.
Logistic regression models were used to study the relation between a positive history for HDP or GDM and prevalence of hypertension or hypercholesterolemia as assessed by a self-reported diagnosis before study enrollment in combination with blood pressure and cholesterol measurements at study entry. Factors measured at study enrollment related to the presence of hypertension and hypercholesterolemia were added as covariables to the model in separate analyses.
Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CI) for risk of CVD and T2D. In all analyses, age from birth to the occurrence of CVD, T2D, or censoring was used as the underlying time scale. HDP and GDM status were modeled as time-dependent variables, changing from at-birth unexposed to exposed at the age of the first pregnancy. We used these models to include cases of CVD and T2D that occurred between the first pregnancy and participation in the study and thus to prevent immortal time bias. 27 Analyses were adjusted for potential confounders in 3 consecutive models. In model I, cohort and both HDP and GDM were included, so we could assess the independent relationship of each of the parameters accounting for study center effects, such as small differences in follow-up procedures and covariate measurements. Subsequently, we added other potential confounders measured at study enrollment to model II: age at study entry, BMI, current smoking, and current alcohol consumption. In model III, we studied the role of potential factors that could mediate the effect of HDP and GDM and CVD risk later in life. Factors included in this model were total cholesterol/high-density lipoprotein ratio, and prevalent hypertension (measured blood pressure or use of antihypertensive medication), both measured at study enrollment, and T2D (only for the CVD outcomes).
All statistical analyses were performed using SPSS (version 22), and P values <0.05 were considered to be statistically significant.
Results
Characteristics of the study population are presented in Table 1 . Of the 22 265 included women, 6157 (27.7%) reported HDP in one of their pregnancies and 1089 (4.9%) reported a history of GDM. Three hundred sixty-six (1.6%) women reported a history of both HDP and GDM. The mean age at enrolment was 53.7 year in the nonexposed, 54.1 year in the HDP, and 51.2 year in the GDM group. Women with GDM and women with a history HDP had a higher BMI. Table 2 describes the relation between a history of HDP and GDM with the presence of hypertension and hypercholesterolemia at study enrollment. Women with a history of HDP were diagnosed with hypertension twice more often (odds ratio 2.12, 95% CI 1.98-2.28). No association was found with hypercholesterolemia. A history of GDM was not associated with a higher prevalence of hypertension or hypercholesterolemia.
Relation of Pregnancy History With Hypertension and Hypercholesterolemia at Study Enrollment
Relation of Pregnancy History With T2D and CVD Events During Follow-Up
Results for the association of a HDP and GDM with CVD events and T2D are presented in Table 3 . In total, 2557 fatal and nonfatal cardiovascular events occurred, out of which 1478 were caused by IHD and 720 by stroke. Adjusted for cohort, age, BMI, current smoking, and current alcohol consumption at study enrollment, HDP was associated with an increased risk for all cardiovascular events (HR 1.21, 95% CI 1.10-1.32), in particular for IHD (HR 1.28, 95% CI 1.14-1.44) and to the development of T2D (HR 1.27, 95% CI 1.11-1.46). To study which factors may mediate the effect of HDP and CVD/T2D risk later in life, additional adjustment was made for the cardiovascular risk factors hypertension and hypercholesterolemia, measured at study enrollment, and Women with a history of GDM had a 4.0-fold increased risk of developing T2D (HR 3.68, 95% CI 2.77-4.90); however, no association was observed between GDM and CVD, also not after adjustment for T2D as intermediate.
Age of Onset of Hypertension and T2D
Of 2567 women from the PROSPECT cohort who were diagnosed with hypertension, self-reported information on age at diagnosis was available. Women with a history of HDP (n=1458) were diagnosed with hypertension 7.7 years earlier since first pregnancy (95% CI 6.9-8.5) at a mean age of 43.5 years (±11.8) than women (n=1109) without such a history (mean age 51.2 years [± 8.5]). The interval between the first pregnancy and diagnosis of hypertension was 18.2±11.9 years versus 26.1±8.9 years, respectively. The time interval between Results obtained with multivariable logistic regression models and expressed as odds ratios with corresponding 95% confidence intervals. Model I: adjustment for cohort and gestational diabetes mellitus (only for hypertensive disorder of pregnancy outcomes) or hypertensive disorder of pregnancy (only for gestational diabetes mellitus outcomes). Model II: additional adjustment for age, BMI, current smoking, and current alcohol consumption at study enrollment. Model III: additional adjustment for history of myocardial infarction and stroke, prevalent diabetes mellitus, total cholesterol/HDL ratio (only for hypertension outcome), and hypertension (only for hypercholesterolemia outcome) at study enrollment. BMI indicates body mass index; and HDL, high-density-lipoprotein. Results obtained with Cox proportional hazard models and expressed as hazards ratios with corresponding 95% confidence intervals. The not exposed group was used as reference. Model I: adjustment for cohort and gestational diabetes mellitus (only for hypertensive disorder of pregnancy outcomes) or hypertensive disorder of pregnancy (only for gestational diabetes mellitus outcomes). Model II: additional adjustment for age, BMI, current smoking, and current alcohol consumption at study enrollment. Model III: additional adjustment for total cholesterol/HDL ratio, prevalent hypertension at study enrollment, and T2D (only for CVD, IHD, and stroke outcome). BMI indicates body mass index; CVD, cardiovascular disease; HDL, high-density lipoprotein; IHD, ischemic heart disease; n, number of events in the exposed group; N, total number of events in this cohort; and T2D, type 2 diabetes mellitus. 
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first pregnancy and diagnosis of T2D was similar in both groups (33.8±9.5 years versus 35.0±9.8 years, respectively). After their first pregnancy, women with GDM were diagnosed with T2D 7.7 years earlier (95% CI 5.8-9.6) at a mean age of 52.8 years (±12.1) than women without such a positive history, who developed T2D at a mean age of 60.2 years (±8.7; time interval between first pregnancy and diagnosis of T2D: 27.5±11.9 years versus 35.4±9.0 years, respectively). In addition, the interval between the first pregnancy and diagnosis of hypertension was also shorter in the GDM group (20.9±9.7 years versus 26.1±8.8 years, respectively).
The first pregnancy is not always the pregnancy in which women had HDP or GDM, as this was not recorded specifically.
Discussion
Women who experience a HDP are diagnosed with hypertension more often and developed this much earlier in life, as opposed to women who do not experience this complication. In addition, women with a history of HDP are at increased risk to develop CVD, mainly because of hypertension. Similarly, women with GDM are diagnosed with T2D and hypertension much earlier in life. This expands the current evidence that HDP and GDM are potentially important indicators for preventive cardiovascular risk management.
Hypertensive Disorder of Pregnancy
Our finding that women with HDP have an increased risk of developing hypertension, diabetes mellitus, and CVD is consistent with the findings of other cohort studies and systematic reviews. [2] [3] [4] 11, 12, [14] [15] [16] [17] However, the magnitude of the relationship between HDP and CVD in our study was smaller than that in these reviews. This is likely a consequence of the self-reportage of HDP by women years after their pregnancy and the type of question we used. We were among the first to quantify the interval in which women with HDP were diagnosed with hypertension after their first pregnancy. In accordance with other long-term follow-up studies of women with HDP, 14, 16 no relation with hypercholesterolemia was found, despite the higher prevalence of obesity in the HDP group.
An additional key finding of this study was that hypertension is an intermediate factor in the development of CVD among women with HDP. Currently, only a few studies have included hypertension and T2D in the statistical models, 16, 18 leaving it unknown whether the pregnancy complications HDP and GDM have an independent impact on the risk of developing CVD or that this increased risk is mediated fully by traditional cardiovascular risk factors. Notwithstanding the lack of information on hypertension between study enrollment and end of follow-up, which can leave room for residual confounding, most of the cardiovascular risk is because of hypertension, with the exception of IHD, for which HDP seems to be an independent risk factor.
BMI is an additional risk factor associated with increased CVD. 28 Although women in the HDP group concerned had a slightly higher BMI, this only affected the risk of future T2D.
Gestational Diabetes Mellitus
From earlier studies, it is known that women experiencing GDM are at increased risk to develop T2D early in life. Of these women, 35% to 60% develop T2D within 10 years. 29 Our findings confirm these results. We observed that the risk of T2D was strongly increased with a HR of 3.7. However, in our cohort, only 15% of the women with GDM developed overt T2D. This low incidence of T2D might be the consequence of the use of only validated cases verified by the participants' general practitioner or pharmacist. The self-reported status might also have an impact on the moderate incidence of T2D in our cohort because women who did not have GDM were included in the GDM group, leading to a lower risk of developing T2D. Furthermore, the relatively low BMI in our cohort might explain the low number of women with both GDM and subsequent T2D because obesity substantially increases the risk of diagnoses of GDM and diabetes mellitus. 30 Also, our risk on the relation between T2D and GDM (HR 3.68; 95% CI 2.77-4.90) is lower than that from the meta-analysis of Bellamy et al (RR 7.4; 95% CI 4.79-11.51). 13 In contrast with other studies, no increased risk was found for long-term cardiovascular morbidity and mortality associated with GDM. 5, 6 Possibly this is the result of the low number of women with GDM in our cohort and the follow-up time between the development of T2D and subsequent CVD. Even though BMI is relatively low in the GDM group, it somewhat affects the risk of future CVD, stroke, and T2D, whereas the risk of IHD is mainly driven by hypertension.
Strengths and Limitations
Some limitations and strengths should be considered. First, the most important limitation of our study is that the diagnosis of high blood pressure and diabetes mellitus in pregnancy was self-reported and not verified by medical records. Although maternal recall of HPD has a specificity of >90%, it has low sensitivity. 31 Therefore, the method of self-report may explain the high prevalence of HDP (27.7%). As a consequence, not only women with severe high blood pressure and preeclampsia are likely to have been included in the exposed group, but also women who only had modest blood pressure elevation without symptoms and signs of preeclampsia. We were unable to validate the information of HDP because we did not have access to the obstetric records of the participants. Furthermore, we were not able to distinguish early onset from late onset preeclampsia. Bellamy et al reported a relative risk of 2.2 for the development of IHD among women with a history of preeclampsia, whereas a relative risk of 7.7 was found for early onset preeclampsia. 3 If the relation with CVD risk is restricted to those with severe or early preeclampsia, we are likely to have underestimated this relationship. The same accounts for the association with cardiovascular risk factors mentioned before. Second, recall bias may have affected the relation under study. In particular, when women with known hypertension at baseline are more likely to remember and report a history of HDP. Third, this study may have had survivor bias. Women with preeclampsia have a higher risk of future disease and poorer survival rates 32 and are therefore less likely to enter the study at an older age. This may have led to a slight underestimation of the observed associations. Fourth, information lacks regarding the question in which particular pregnancy the included women had HDP or GDM.
Only the age at the first pregnancy and whether the woman by guest on August 29, 2017 http://hyper.ahajournals.org/ Downloaded from had a HDP or GDM in one of her pregnancies was known. Equally, the same applies for the unexposed women where the time between the first pregnancy and development of hypertension, T2D, and CVD was used in identical fashion. Hence, the results are most unlikely to be affected hereby. Moreover, HDP predominantly affects first pregnancies. 33 Finally, although the sitting position is the standard for measurement of blood pressure, in the EPIC-NL study, blood pressure was determined in supine position. This might have had an impact on the blood pressure levels. However, in the literature, it is unclear to what extent and in which direction the blood pressure differs between the supine and the seated position because some studies observed higher systolic and diastolic blood pressure in sitting position, whereas others have found greater values in supine positions, or no significant differences. 34 Moreover, blood pressure was measured in the same position in all groups of this study. Therefore, we do not expect that differences in blood pressure levels would lead to a different risk on the development of hypertension after a pregnancy complication.
The strengths of our study are the large sample size and the availability of information on potential confounders for the development of CVD. A further strength is the information on prevalent and incident T2D, which was verified by questionnaires to the participants' general practitioner or pharmacist. Also, by performing time-dependent analyses, we were able to include cases of T2D and CVD that occurred between the first pregnancy and many years later at study entry. This makes our results more complete and reliable.
Perspectives
An important novel finding of this study is that the age of onset of hypertension in women with HDP is on average 7.7 years earlier than the age of onset in women without HDP. The same applies for the age of onset of T2D in women with GDM, with a mean difference of 7.7 years. This information is important when one wants to conduct or initiate screening programs in women with a history of HDP or GDM to detect those with an unfavorable risk factor profile as early as possible. Improvements of lifestyle and other modifiable risk factors, such as hypertension and obesity, in these women might reduce their risk of both recurrent pregnancyrelated cardiovascular complications and future CVD (risk factors). Results obtained with multivariable logistic regression models and expressed as odds ratios with corresponding 95% confidence intervals.
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